文献速递妇科

维持性激素治疗与晚期低级别浆液性卵巢癌总生存期的关联:风险集匹配回顾性研究

The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
PubMed 文献 · Gynecol Oncol · 2024-08-22

本研究为多机构观察性研究,纳入2004年1月1日至2019年12月31日在美国癌症委员会认证项目中诊断的III或IV期低级别浆液性卵巢癌患者,采用风险集倾向评分匹配比较诊断后6个月内开始维持性激素治疗者与未开始者的五年内全因死亡风险。匹配后激素治疗组225例、对照组225例,激素治疗与死亡风险降低相关(HR 0.60;95%CI 0.38-0.94),60个月生存率75%对65%。

要点

  • 匹配队列中维持性激素治疗与死亡风险降低相关(HR 0.60;95%CI 0.38-0.94)。
  • 激素治疗组60个月生存率为75%,对照组为65%。
  • 研究为回顾性观察性设计,结果需进一步研究验证。

核心结论

  • 低级别浆液性卵巢癌初始治疗后,维持性激素治疗与观察相比与总生存期改善相关。

研究设计与样本

  • 多机构观察性研究,纳入2004年1月1日至2019年12月31日在美国癌症委员会认证项目中诊断的III或IV期低级别浆液性卵巢癌患者。
  • 采用风险集倾向评分匹配,将诊断后6个月内接受激素治疗的患者与同期未开始激素治疗的对照进行匹配。
  • 主要结局为激素治疗或观察开始后五年内全因死亡风险。
  • 共296例患者在诊断后6个月内开始维持性激素治疗,2805例潜在对照。
  • 匹配后识别225例激素治疗患者和225例未治疗对照,两组测量的协变量相似。

主要发现

  • 激素治疗组更常在学术医疗中心治疗(55% vs 44%),诊断年份更晚(2018-2019年诊断者62% vs 23%),初始治疗中常未接受化疗(45% vs 17%)。
  • 匹配队列中,激素治疗与死亡风险降低相关(HR 0.60;95%CI 0.38-0.94)。
  • 匹配队列中,激素治疗组60个月生存率为75%,对照组为65%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We conducted a multi-institutional observational study to investigate whether maintenance hormone therapy following primary treatment of low-grade advanced-stage ovarian cancer (LGSOC) is associated with an overall survival advantage. METHODS: We included patients with histologically confirmed stage III or IV LGSOC diagnosed between Jan 1, 2004, and Dec 31, 2019, treated in Commission on Cancer-accredited cancer programs in the US. Patients who received hormone therapy within six months of diagnosis were matched to controls who did not initiate hormone therapy during this timeframe by risk-set propensity score matching. The primary outcome was the risk of death from any cause within five years of initiation of HT or observation. RESULTS: There were 296 patients who initiated maintenance hormone therapy within six months of diagnosis and 2805 potential controls. Patients who received hormone therapy were more often treated in academic medical centers (55% vs. 44%), diagnosed later in the study period (62% vs. 23% diagnosed in 2018-2019), and frequently received no chemotherapy during initial treatment (45% vs. 17%). After risk set propensity score matching, we identified 225 patients treated with HT and 225 untreated controls who were otherwise similar with respect to measured covariates. In the matched cohort, hormone therapy was associated with a reduction in the risk of death (hazard ratio 0.60; 95% CI 0.38-0.94), corresponding to a 60-month survival of 75% compared with 65%. CONCLUSIONS: Following primary management of LGSOC, maintenance hormone therapy was associated with improved overall survival compared with observation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Barakzai SK, Bregar AJ, Del Carmen MG, et al. The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study. Gynecol Oncol. 2024. PMID: 39178527. doi:10.1016/j.ygyno.2024.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。